Odyssey Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
OD-001 showed 27% clinical remission at 20 mg BID, with biomarker and tissue findings supporting the dose and RIPK2 mechanism. Phase II-B monotherapy and vedolizumab combination trials were planned, with induction readouts targeted for H2 2027.
-
The forum highlighted a robust pipeline targeting autoimmune and inflammatory diseases, with lead RIPK2 inhibitor showing promising phase IIA results in ulcerative colitis and plans for combination and monotherapy trials. Additional programs in SLC15A4 and TNFR2 agonism are advancing, supported by strong financials into 2028.
-
The conference highlighted an innovation-driven pipeline targeting upstream immune pathways for durable remissions in inflammatory and autoimmune diseases. OD-001 showed promising phase IIa results in IBD, with rapid efficacy even in refractory patients. Multiple clinical readouts are expected by 2027, with a focus on rapid development and commercialization.